Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
Data on changes in liver sinusoidal endothelial cells (LSECs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and their response to treatment are limited. This study demonstrates that LSEC capillarisation is already present in the lobular zone of the liver of patients and rats at the stage of isolated steatosis, before metabolic dysfunction-associated steatohepatitis (MASH) onset, and progresses with liver fibrosis, and to a lesser extent with liver inflammation. Lanifibranor treatment, a pan-peroxisome proliferator-activated receptor agonist currently tested in a phase III clinical trial, improves LSEC capillarisation but also intrahepatic vascular resistance and portal pressure in MASLD. Targeting LSECs appears to be a promising approach to improve MASH.
Authors
- Manal F. Abdelmalek (ORCID: https://orcid.org/0000-0002-5001-8618)
- Christophe Casteleyn (ORCID: https://orcid.org/0000-0003-2676-0756)
- Wilhelmus J. Kwanten (ORCID: https://orcid.org/0000-0001-9474-6695)
- Martine Baudin
- Jean-Louis Junien
- Shivani Chotkoe (ORCID: https://orcid.org/0000-0003-2333-302X)
- Pierre Bédossa (ORCID: https://orcid.org/0000-0002-8487-7322)
- Guillaume Wettstein
- Lucile Dzen
- Pierre‐Emmanuel Rautou (ORCID: https://orcid.org/0000-0001-9567-1859)
- Michael Cooreman (ORCID: https://orcid.org/0009-0007-3230-7591)
- Winnok H. De Vos (ORCID: https://orcid.org/0000-0003-0960-6781)
- Joris De Man
- Valérie Paradis (ORCID: https://orcid.org/0000-0003-3142-3762)
- Louise Biquard (ORCID: https://orcid.org/0000-0002-1356-6543)
- Philippe Huot-Marchand
- Denise van der Graaff (ORCID: https://orcid.org/0000-0001-8179-6802)
- Pierre Broqua
- Sven Francque (ORCID: https://orcid.org/0000-0002-7527-4714)
- Luisa Vonghia (ORCID: https://orcid.org/0000-0002-3999-9259)
- Yao Liu (ORCID: https://orcid.org/0000-0002-4330-2389)
- Sofie Thys
- Miguel Albuquerque (ORCID: https://orcid.org/0000-0001-7311-1623)
- Jean‐Louis Abitbol
Institutions
- University of Antwerp (BE)
- Inserm (FR)
- Capital Medical University (CN)
- Université Paris Cité (FR)
- Hôpital Beaujon (FR)
- Ghent University (BE)
- Antwerp Management School (BE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Antwerp University Hospital (BE)
- Mayo Clinic in Arizona (US)
- Inventiva (France) (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Beijing Hospital of Traditional Chinese Medicine (CN)
- Régie Autonome des Transports Parisiens (France) (FR)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101366
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Inventiva Pharma